
Semaglutide reduced cardiovascular events by 20% in certain adults
November 13, 2023
Semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes, according to new research. Semaglutide is primarily prescribed for adults with type 2 diabetes but is also approved for chronic weight management ... Read More